AI is revolutionizing countless industries, but its biggest impact may be felt in medicine. Machine learning has proved capable of identifying signs of disease in medical images and records, and it may become invaluable for analyzing vast genomic data sets for clues as to the origins of different disorders. Benevolent AI, headquartered in London, is working to apply the latest AI techniques to the identification and development of novel drug compounds. The company’s CEO, Ken Mulvaney, met with MIT Technology Review’s senior editor for AI, Will Knight, to discuss AI’s relevance to drug discovery and medicine, and to talk about his company’s ambitious plans.
This startup wants to copy you into an embryo for organ harvesting
With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.
VR is as good as psychedelics at helping people reach transcendence
On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.
This artist is dominating AI-generated art. And he’s not happy about it.
Greg Rutkowski is a more popular prompt than Picasso.
This nanoparticle could be the key to a universal covid vaccine
Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.